Study at a glance
How do vitamin D cut-offs and targets affect health decisions?
This review explains how vitamin D cut-offs and targets affect health decisions and research. A cut-off separates categories or triggers an action. A target is a blood level someone aims to reach. Both commonly use 25-hydroxyvitamin D, the usual blood measure of vitamin D status.
Why does the vitamin D cut-off matter?
Raising a cut-off can increase the number labelled deficient without changing anyone’s actual blood level. It can also change who receives testing or treatment and who enters a study. Laboratory differences can move a result across a cut-off without a matching change in the body.
How can vitamin D cut-offs affect study findings?
If a treatment benefits mainly people with very low levels, including many people with adequate levels could make that benefit harder to detect. However, choosing a higher cut-off does not automatically identify people who benefit. Testing many cut-offs after seeing the results can produce an apparently favourable result by chance. Such findings need confirmation in further research.
What evidence is needed for a vitamin D target?
The Endocrine Society’s 2024 review did not establish cut-offs predicting specific supplement benefits in generally healthy populations. This does not remove the importance of severe deficiency. A target may be useful in a particular clinical setting, but needs evidence that achieving it improves a relevant outcome. Putting people in a category and showing that treatment helps are separate questions.
Read the full article below ↓The distinction between a vitamin D threshold and a vitamin D target is not merely semantic. It changes who is classified as deficient or insufficient, who is tested or treated, how supplementation trials are designed, how prevalence estimates are calculated and how apparently conflicting guidelines are interpreted. A threshold establishes an action or classification boundary for a defined purpose. A target specifies a concentration or range that clinicians or researchers intend to achieve. When those two functions are treated as interchangeable, clinical decisions and research conclusions can become more certain than the underlying evidence allows. This study develops the framework in Vitamin D Thresholds vs Targets. For the concise Twin, see Clinical and Research Implications of Vitamin D Thresholds Versus Targets: Study Summary.
Classification depends on what the cut-off is meant to do
A 25-hydroxyvitamin D [25(OH)D] cut-off can serve several different roles. It may identify a level associated with increased risk of rickets or osteomalacia. It may represent a population adequacy value. It may divide research participants into exposure groups. It may trigger treatment in a clinical pathway. Or it may be used as a target against which supplementation success is judged.
Those uses are not equivalent. If a threshold designed to detect clinically important deficiency is converted into a target, everyone below the target may appear undertreated even when the evidence only established risk much lower on the continuum. Conversely, if a population adequacy value is treated as an individual diagnostic boundary, people close to the threshold may be classified too rigidly despite biological and analytical variability.
This is why Vitamin D Deficiency Definitions must be read alongside the purpose of the definition rather than simply compared by number.
Changing a target changes the apparent size of the problem
One of the most immediate consequences of choosing a higher target is epidemiological. If one framework treats 20 ng/mL as adequate for most of the population and another uses 30 ng/mL as the lower boundary of sufficiency, the estimated prevalence of inadequacy can expand dramatically even when the underlying distribution of measured 25(OH)D has not changed.
This is not merely a statistical curiosity. Prevalence estimates influence public concern, laboratory flags, treatment rates, supplementation advice and health-system costs. A population can appear to have widespread deficiency under one classification and much lower deficiency under another. The apparent disagreement may arise partly because the systems are answering different questions rather than because one has measured a different biological reality.
The interpretive problem becomes even more apparent in Population Reference Ranges Explained, where population distributions, adequacy thresholds and disease definitions must be kept conceptually separate.
Threshold choice can change who enters a clinical pathway
In clinical practice, a threshold can trigger testing, diagnosis, supplementation or further investigation. A higher target can also lead to repeated measurement until a patient reaches a desired concentration. These decisions have practical consequences because vitamin D testing and supplementation occur at very large scale.
A threshold is most defensible when the action it triggers is supported by evidence for the population concerned. Severe deficiency, especially in patients with skeletal symptoms or relevant risk factors, is not conceptually equivalent to a generally healthy person whose 25(OH)D is modestly below a proposed optimisation target. The biological continuum is the same, but the clinical certainty and expected treatment benefit are not necessarily the same.
This distinction is particularly relevant to Vitamin D Insufficiency Explained. The intermediate category between clear deficiency and accepted adequacy has historically carried much of the controversy because it can represent reduced vitamin D supply without establishing that every person in that range has clinically important dysfunction.
Research classification can create apparent treatment effects
Thresholds also shape randomised trials and observational studies. Investigators may recruit only participants below a chosen concentration, stratify participants according to baseline status or perform subgroup analyses using predefined cut-offs. The resulting conclusions can depend heavily on where those boundaries are placed.
If a treatment genuinely benefits only people with very low vitamin D status, a trial enrolling a broadly sufficient population may dilute the effect. That is a legitimate methodological concern. But choosing a higher threshold does not automatically solve it. A subgroup cut at 30 ng/mL may contain many people whose physiology and treatment response are not meaningfully different from those just above 30 ng/mL. The cut-off can create an apparently discrete subgroup out of an underlying continuous distribution.
Post hoc threshold searching creates another problem. If researchers test many possible cut-offs until one yields a favourable result, the selected threshold can look biologically meaningful even when it partly reflects statistical chance. A clinically actionable target should therefore be supported by reproducible evidence rather than by one convenient division of a continuous biomarker.
Assay variation can move people across fixed boundaries
25(OH)D measurement is sufficiently robust to remain the central biochemical measure of vitamin D status, but historical assay variability has materially affected classification. Standardisation studies have demonstrated that reanalysing or recalibrating population data can shift mean concentrations and alter the percentage of people classified as having low vitamin D status.
This creates a particular problem when a target is treated as a sharp boundary. A small analytical difference around 20 or 30 ng/mL can change a categorical label even when there has been no meaningful biological change in the person being measured. The closer the clinical logic comes to “below this exact number is inadequate, above it is optimal,” the more vulnerable the system becomes to analytical noise and biological variability.
The same concern is reflected in Why Vitamin D Insufficiency Is Not a Universal Cut-Off, where measurement variation is one reason intermediate categories should not be interpreted as precise biological switches.
Guideline disagreement may reflect different evidential purposes
Guidelines have historically disagreed about vitamin D deficiency, insufficiency and sufficiency. The familiar contrast between approximately 20 ng/mL and 30 ng/mL illustrates how apparently small numerical differences can carry large practical consequences.
The Institute of Medicine derived population dietary requirements primarily from skeletal evidence and judged that 20 ng/mL would meet the requirements of nearly all individuals under its model. The 2011 Endocrine Society guideline used a different clinical framework and promoted a higher sufficiency boundary of 30 ng/mL, partly drawing on PTH, calcium-absorption and other evidence. These positions were often described as if one organisation believed vitamin D mattered and the other did not. The actual disagreement was more specific: what endpoints were sufficiently established, what population was being addressed and what evidential threshold justified a higher actionable concentration.
The 2024 Endocrine Society guideline subsequently changed that position for generally healthy populations. After reviewing newer randomised evidence, the panel concluded that available trials did not establish 25(OH)D thresholds that specifically predicted meaningful benefit from supplementation and no longer endorsed the previous 30 ng/mL sufficiency target in generally healthy people.
This shift is important because it demonstrates that a target is not simply a permanent physiological fact. It is an evidence-dependent clinical construct that may change when the outcome evidence changes. Vitamin D Insufficiency: Physiology, Thresholds and Interpretation: Evidence Synthesis develops the same point from the perspective of insufficiency.
Outcome-specific thresholds may differ
Another reason not to collapse threshold and target language is that vitamin D could theoretically have different relevant concentrations for different outcomes. The 25(OH)D concentration associated with substantially increased osteomalacia risk need not equal the concentration associated with maximal PTH suppression, fracture reduction, immune effects or another endpoint.
A universal target would require either evidence that these outcomes converge around the same concentration or a principled reason to select one outcome as dominant. Where such evidence is absent, a broad claim that one number represents “optimal vitamin D” risks concealing the endpoint-specific nature of the science.
This is the practical significance of Vitamin D Sufficiency Explained. Sufficiency can mean adequate for a defined function without implying maximal benefit for every possible vitamin D-responsive process.
Targets can encourage treatment-to-number thinking
When a biomarker target becomes culturally established, it can shift clinical attention from the patient’s context to the number itself. A patient whose 25(OH)D rises substantially but remains just below the target may be regarded as unsuccessfully treated, while another patient just above the target may be regarded as fully replete. That binary interpretation may be convenient administratively but does not reflect continuous physiology.
This does not mean targets should never be used. Medicine frequently uses targets where clinical trials show that achieving a range improves outcomes. The requirement is evidential: the target should earn its status rather than inheriting it from a nearby deficiency threshold.
Research should separate classification from causal prediction
A useful research framework asks two separate questions. First, at what concentration does the risk of clearly inadequate vitamin D physiology materially increase? Second, at what baseline concentration, if any, does raising vitamin D status improve a specified clinical outcome? The first identifies deficiency. The second identifies treatment responsiveness or a potentially useful target.
Those values may overlap, but they should not be assumed to be identical. The 2024 Endocrine Society review is important precisely because it sought evidence that baseline 25(OH)D thresholds predicted benefit from supplementation and found the available trial evidence insufficient to define such thresholds for the generally healthy populations considered.
Clinical interpretation should remain conditional
For clinicians and readers, the safest interpretive question is not “What is the correct vitamin D number?” but “What decision is this number being used to make?” A level can be low enough to raise concern about deficiency without proving a universal treatment target. A higher target can be appropriate in a specific clinical pathway without establishing that it should define sufficiency for the general population.
Distinguishing Vitamin D Insufficiency from Deficiency and Sufficiency: Full Study shows why deficiency, insufficiency and sufficiency labels themselves already contain interpretive assumptions. Adding a target without distinguishing its function compounds that ambiguity.
The practical consequence
A deficiency threshold is a boundary for concern or action. A target is an intended destination. Research and clinical practice become unreliable when those roles are silently merged. The higher a proposed target sits above the region of clearly established deficiency, the greater the need for direct evidence that achieving the target improves a meaningful outcome.
This distinction reduces false disagreement between guidelines, prevents prevalence estimates from being mistaken for disease burden, limits treatment-to-number thinking and encourages trials to test clinically meaningful response rather than assume that one biomarker cut-off defines biological optimisation.
Scientific sources
Ross AC, Manson JE, Abrams SA, et al. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know. Journal of Clinical Endocrinology & Metabolism. 2011;96(1):53-58. PMID: 21118827. PMCID: PMC3046611. DOI: 10.1210/jc.2010-2704.
Sempos CT, Heijboer AC, Bikle DD, et al. Vitamin D assays and the definition of hypovitaminosis D: results from the First International Conference on Controversies in Vitamin D. British Journal of Clinical Pharmacology. 2018;84(10):2194-2207. DOI: 10.1111/bcp.13652.
Demay MB, Pittas AG, Bikle DD, et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2024;109(8):1907-1947. DOI: 10.1210/clinem/dgae290.
McCartney CR, McDonnell ME, Corrigan MD, Lash RW. Vitamin D Insufficiency and Epistemic Humility: An Endocrine Society Guideline Communication. Journal of Clinical Endocrinology & Metabolism. 2024;109(8):1948-1954. DOI: 10.1210/clinem/dgae322.
Gallagher JC, Yalamanchili V, Smith LM. The Effect of Vitamin D on Calcium Absorption in Older Women. Journal of Clinical Endocrinology & Metabolism. 2012;97(10):3550-3556. PMID: 22855333. PMCID: PMC3462946. DOI: 10.1210/jc.2012-2020.
Related reading
Physiological Limitations of Vitamin D Deficiency Cut-Offs and Diagnostic Thresholds: Full Study
Review the physiological limitations of vitamin D deficiency cutoffs, including PTH, calcium intake, assay variation and individual biological differences.
Read more →Diverse Effects of Combinations of Maternal-Neonatal VDR Polymorphisms and 25-Hydroxyvitamin D Concentrations on Neonatal Birth Anthropometry: Functional Phenocopy Variability Dependence, Highlights the Need for Targeted Maternal 25-Hydroxyvitamin D Cut-Offs during Pregnancy
The aim of this study was to evaluate the combined effect of maternal and neonatal VDR polymorphisms (ApaI, TaqI, BsmI, FokI, Tru9I) and different maternal and neonatal 25(OH)D cut-offs on neonatal birth anthropometry.
Original paper ↗Read more →Why Vitamin D Insufficiency Is Not a Universal Cut-Off
Learn why vitamin D insufficiency has no universal numerical cut-off and how physiology, guideline purpose, population thresholds and measurement variability affect interpretation.Page type: Context.
Read more →Clinical and Research Implications of Vitamin D Thresholds Versus Targets: Study Summary
A concise evidence summary of how vitamin D thresholds and targets influence clinical decisions, research design, guideline comparisons and interpretation.
Read more →Vitamin D Thresholds vs Targets
Explore the difference between vitamin D thresholds and targets, why numbers vary between people, and how physiology and context shape meaningful interpretation.
Read more →A Narrative Review of the Evidence for Variations in Serum 25-Hydroxyvitamin D Concentration Thresholds for Optimal Health
Vitamin D3 has many important health benefits.
Original paper ↗Read more →Applying Machine Learning to Determine 25(OH)D Threshold Levels Using Data from the AMATERASU Vitamin D Supplementation Trial in Patients with Digestive Tract Cancer
Vitamin D supplementation improved 5-year relapse-free survival (RFS) compared with placebo in patients with intermediate 25(OH)D levels (18 to 28 ng/mL): vitamin D, 84% vs.
Original paper ↗Read more →Serum 25-hydroxyvitamin D threshold and risk of rickets in young children: a systematic review and individual participant data meta-analysis to inform the development of dietary requirements for vitamin D
The objective of this systematic review was to determine a minimum serum 25-hydroxyvitamin D (25OHD) threshold based on the risk of having rickets in young children.
Original paper ↗Read more →Threshold of 25(OH)D and consequently adjusted parathyroid hormone reference intervals: data mining for relationship between vitamin D and parathyroid hormone
By recruiting reference population, we aimed to (1): estimate the 25(OH)D threshold that maximally inhibits the PTH, which can be defined as the cutoff value for vitamin D sufficiency; (2) establish the PTH reference interval (RI) in population with sufficient vitamin D.
Original paper ↗Read more →Vitamin D Insufficiency: Physiology, Thresholds and Interpretation: Evidence Synthesis
An evidence synthesis integrating vitamin D insufficiency physiology, thresholds, guideline differences and measurement uncertainty to support careful interpretation.
Read more →Association between serum 25-hydroxyvitamin D levels and Early Vascular Aging in young and middle-aged adults
Participants were categorized into EVA group (n = 687) and control group (n = 1360) based on brachial ankle pulse wave velocity (baPWV).
Original paper ↗Read more →Association between serum 25-hydroxyvitamin D, nutritional status, and inflammatory markers in sepsis patients with and without sarcopenia
The current study aimed to address this gap by exploring 25(OH)D cut-off values with potential discriminatory value for sepsis and sepsis with sarcopenia, particularly in a Chinese patient population where relevant data remain scarce.
Original paper ↗Read more →Association between Suboptimal 25-Hydroxyvitamin D Status and Overweight/Obesity in Infants: A Prospective Cohort Study in China
This study aimed to investigate whether 25-hydroxyvitamin D (25(OH)D) concentrations are correlated to overweight/obesity in infants and to explore a threshold of 25(OH)D.
Original paper ↗Read more →Associations between serum 25(OH)D concentrations and prevalent asthma among children living in communities with differing levels of urbanization: a cross-sectional study
Prior evidence suggests that vitamin D deficiency may increase the risk of asthma and atopy and impair pulmonary function in children.
Original paper ↗Read more →Diagnostic Value of Serum 25-Hydroxyvitamin D Levels in Predicting Poor Glycemic Control Among Children with Type 1 Diabetes Mellitus: A ROC Curve and Decision Curve Analysis
This study aimed to determine the prevalence of vitamin D deficiency among children and adolescents with T1DM and to evaluate its relationship with glycemic control.
Original paper ↗Read more →Dose-Response Relationship Between Serum 25(OH)D and the Risk of Abnormal Glycemic Status in Chinese Older Adults
Background/Objectives: The relationship between serum 25-hydroxyvitaminD (25(OH)D) concentration and the risk of abnormal glycemic status remains contradictory.
Original paper ↗Read more →No effect of 25-hydroxyvitamin D supplementation on the skeletal muscle transcriptome in vitamin D deficient frail older adults
The aim of this study was to investigate the effect of calcifediol (25-hydroxycholecalciferol) on whole genome gene expression in skeletal muscle of vitamin D deficient frail older adults.
Original paper ↗Read more →Non-Linear Relationship between Serum 25-Hydroxyvitamin D and Hemoglobin in Korean Females: The Korean National Health and Nutrition Examination Survey 2010 to 2011
Anemia and vitamin D deficiency are both important health issues; however, the nature of the association between vitamin D and either hemoglobin or anemia remains unresolved in the general population.
Original paper ↗Read more →Plasma 25-hydroxyvitamin D level and the risk of frailty among Chinese community-based oldest-old: evidence from the CLHLS study
The aim of this study was to examine the association between plasma 25-hydroxyvitamin D [25(OH)D] levels and the risk of frailty among the Chinese community based oldest-old.
Original paper ↗Read more →Quantitative Ultrasound Assessment of Skeletal Muscle Microvascularity in Relation to Serum 25-Hydroxyvitamin D Concentrations
In contrast, VI values were significantly higher in participants with higher serum 25(OH)D levels across all examined muscles (p < 0.001).
Original paper ↗Read more →Relationship Between Total 25-Hydroxyvitamin D and Parathyroid Hormone Concentrations During Early Gestation in Indian Women
The inverse relationship between 25(OH)D and parathyroid hormone (PTH) concentrations was examined to define the breakpoint at which PTH was maximally suppressed using a segmented regression analysis.
Original paper ↗Read more →Original sources
The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know
Published in Journal of Clinical Endocrinology & Metabolism (2011).
Publication details
Ross AC, Manson JE, Abrams SA, et al. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know. Journal of Clinical Endocrinology & Metabolism. 2011;96(1):53-58. PMID: 21118827. PMCID: PMC3046611. DOI: 10.1210/jc.2010-2704.
Vitamin D assays and the definition of hypovitaminosis D: results from the First International Conference on Controversies in Vitamin D
Published in British Journal of Clinical Pharmacology (2018).
Publication details
Sempos CT, Heijboer AC, Bikle DD, et al. Vitamin D assays and the definition of hypovitaminosis D: results from the First International Conference on Controversies in Vitamin D. British Journal of Clinical Pharmacology. 2018;84(10):2194-2207. DOI: 10.1111/bcp.13652.
Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline
Published in Journal of Clinical Endocrinology & Metabolism (2024).
Publication details
Demay MB, Pittas AG, Bikle DD, et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2024;109(8):1907-1947. DOI: 10.1210/clinem/dgae290.
Vitamin D Insufficiency and Epistemic Humility: An Endocrine Society Guideline Communication
Published in Journal of Clinical Endocrinology & Metabolism (2024).
Publication details
McCartney CR, McDonnell ME, Corrigan MD, Lash RW. Vitamin D Insufficiency and Epistemic Humility: An Endocrine Society Guideline Communication. Journal of Clinical Endocrinology & Metabolism. 2024;109(8):1948-1954. DOI: 10.1210/clinem/dgae322.
The Effect of Vitamin D on Calcium Absorption in Older Women
Published in Journal of Clinical Endocrinology & Metabolism (2012).
Publication details
Gallagher JC, Yalamanchili V, Smith LM. The Effect of Vitamin D on Calcium Absorption in Older Women. Journal of Clinical Endocrinology & Metabolism. 2012;97(10):3550-3556. PMID: 22855333. PMCID: PMC3462946. DOI: 10.1210/jc.2012-2020.